Here are the S-1 registration statements from Crescent Biopharma, Inc. (CBIO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow CBIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CBIO filings page.
Crescent Biopharma, Inc. is registering 19,710,257 ordinary shares for resale by existing investors who participated in prior private financings. These “Resale Shares” include ordinary shares already outstanding, as well as shares issuable from pre-funded warrants and Series A non-voting convertible preferred shares held by Fairmount Healthcare Fund II L.P. and other accredited investors.
The company itself is not selling shares in this offering and will not receive proceeds from resales, other than the nominal cash exercise price if holders exercise pre-funded warrants. As of December 31, 2025, Crescent had 27,556,767 ordinary shares outstanding and 2,890 Series A non-voting convertible preferred shares outstanding.
Crescent is a clinical-stage oncology company developing CR-001, a PD-1 x VEGF bispecific antibody intended as a next-generation immunotherapy backbone, alongside antibody-drug conjugates CR-002 and CR-003, with multiple Phase 1/2 trials planned to begin in 2026. The prospectus highlights that the company has a limited operating history, significant accumulated losses, no approved products, and expects to continue incurring substantial losses while advancing its pipeline.